After rigorous validation of an antibody for CD40, quantitative immunofluorescence was employed to screen for CD40 expression on tumor cells across nine cancer types, and to complete large cohort, population-based assessments in NSCLC, ovarian cancer, and pancreatic adenocarcinoma. Here, CD40 is linked to ovarian cancer.